Literature DB >> 25594705

MALDI imaging-based classification of hepatocellular carcinoma and non-malignant lesions in fibrotic liver tissue.

C Marquardt1, T Tolstik1, C Bielecki1, R Kaufmann2, A C Crecelius3, U S Schubert3, U Settmacher2, A Stallmach1, O Dirsch4.   

Abstract

Histopathologic differentiation of nodular lesions in cirrhotic liver is difficult even for experienced hepatopathologists especially regarding diagnosis of hepatocellular carcinoma (HCC) in biopsies. For this reason, new tissue markers are needed to reinforce histopathologic decision-making. With advances in molecular techniques, proteomic analysis may help to confirm the diagnosis of HCC. Matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) is a powerful technology which allows to determine and to localize proteins directly in tissue sections. Using MALDI IMS proteomic patterns of cryosections with lesions of HCC (n = 15) and non-malignant fibrotic liver tissue (n = 11) were investigated to establish a classification model of HCC, which was validated in an independent set of tissue to distinguish HCC (n = 10) from regenerative nodules (n = 8). By correlating generated mass spectrometric images with the histology of the tissue sections we found that the expression of 4 proteins as indicated by m/z 6274, m/z 6647, m/z 6222 and m/z 6853 was significantly higher in HCC tissue than in non-tumorous liver tissue. The generated classification model based on the most significant 3 differentially expressed proteins allowed a reliable prediction of benign and malignant lesions in fibrotic liver tissue with a sensitivity and specificity of 90 % in the validation set. The identified MALDI IMS proteomic signature can be diagnostically helpful to allow simplifying the diagnostic process and minimize the risks of delays in establishing the objective final diagnosis and initiating treatment of patients with HCC. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25594705     DOI: 10.1055/s-0034-1385398

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  4 in total

Review 1.  Evolution of the liver biopsy and its future.

Authors:  Dhanpat Jain; Richard Torres; Romulo Celli; Jeremy Koelmel; Georgia Charkoftaki; Vasilis Vasiliou
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

Review 2.  Advances in MALDI imaging mass spectrometry of proteins in cardiac tissue, including the heart valve.

Authors:  Peggi M Angel; H Scott Baldwin; Danielle Gottlieb Sen; Yan Ru Su; John E Mayer; David Bichell; Richard R Drake
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2017-03-21       Impact factor: 3.036

3.  Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma.

Authors:  Yi-Chieh Yang; Ming-Hsien Chien; Tsung-Ching Lai; Min-Che Tung; Yi-Hua Jan; Wei-Ming Chang; Shih-Ming Jung; Ming-Huang Chen; Chun-Nan Yeh; Michael Hsiao
Journal:  J Biomed Sci       Date:  2021-04-22       Impact factor: 8.410

Review 4.  Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma.

Authors:  Felix Marsh-Wakefield; Angela L Ferguson; Ken Liu; Cositha Santhakumar; Geoffrey McCaughan; Umaimainthan Palendira
Journal:  Ther Adv Med Oncol       Date:  2022-07-22       Impact factor: 5.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.